BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23495824)

  • 1. Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin.
    Bickelhaupt S; Pazahr S; Chuck N; Blume I; Froehlich JM; Cattin R; Raible S; Bouquet H; Bill U; Rogler G; Frei P; Boss A; Patak MA
    Neurogastroenterol Motil; 2013 Jun; 25(6):467-73. PubMed ID: 23495824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease.
    Höög CM; Bark LÅ; Broström O; Sjöqvist U
    Scand J Gastroenterol; 2014 Sep; 49(9):1084-90. PubMed ID: 24853318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between morphological expansion and impairment of intra- and prelesionary motility in inflammatory small bowel lesions in patients with Crohn's disease - preliminary data.
    Bickelhaupt S; Wurnig M; Boss A; Patak MA
    Eur J Radiol; 2014 Jul; 83(7):1044-1050. PubMed ID: 24794863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation between active and chronic Crohn's disease using MRI small-bowel motility examinations - initial experience.
    Bickelhaupt S; Froehlich JM; Cattin R; Patuto N; Tutuian R; Wentz KU; Culmann JL; Raible S; Bouquet H; Bill U; Patak MA
    Clin Radiol; 2013 Dec; 68(12):1247-53. PubMed ID: 23973163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers and MR imaging findings as predictors of crohn disease activity in patients scanned by contrast-enhanced MR enterography.
    Quaia E; Cabibbo B; Sozzi M; Gennari AG; Pontello M; Degrassi F; Cova MA
    Acad Radiol; 2014 Oct; 21(10):1225-32. PubMed ID: 24998692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
    Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
    Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small bowel strictures in Crohn's disease: a quantitative investigation of intestinal motility using MR enterography.
    Menys A; Helbren E; Makanyanga J; Emmanuel A; Forbes A; Windsor A; Punwani S; Halligan S; Atkinson D; Taylor SA
    Neurogastroenterol Motil; 2013 Dec; 25(12):967-e775. PubMed ID: 24028647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of 18F-FDG PET/MRE Metrics with Inflammatory Biomarkers in Patients with Crohn's Disease: A Pilot Study.
    Domachevsky L; Leibovitzh H; Avni-Biron I; Lichtenstein L; Goldberg N; Nidam M; Groshar D; Bernstine H; Ben-Bassat O
    Contrast Media Mol Imaging; 2017; 2017():7167292. PubMed ID: 29097934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
    Schaffer T; Schoepfer AM; Seibold F;
    J Crohns Colitis; 2014 Sep; 8(9):1125-32. PubMed ID: 24636141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography.
    Arai T; Takeuchi K; Miyamura M; Ishikawa R; Yamada A; Katsumata M; Igarashi Y; Suzuki Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):56-62. PubMed ID: 27565523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
    Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
    Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.
    Lönnkvist MH; Theodorsson E; Holst M; Ljung T; Hellström PM
    Scand J Gastroenterol; 2011 Apr; 46(4):420-7. PubMed ID: 21114432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
    Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.